BRD6688
Based on 1 publication(s) in Google Scholar
BRD6688 is a selective HDAC inhibitor with IC50 values of 21 nM and 100 nM for HDAC1 and HDAC2, respectively. BRD6688 induces histone H4K12 and H3K9 acetylation. BRD6688 decreases CK2-induced HDAC2 phosphorylation. BRD6688 induces macrophage M1 to M2 polarization and renal cell proliferation. BRD6688 is used in research on neurodegenerative diseases, acute kidney injury, pain, and anxiety disorders.
For research use only. We do not sell to patients.
- Purity : 98.06%
- CAS No.: 1404562-17-9
- Formula: C16H18N4O
- Molecular Weight:282.34
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) BRD6688
More
Biological Activity
Description
IC50 & Target
[1]|
HDAC1 21 nM (IC50) |
HDAC2 100 nM (IC50) |
In Vitro
BRD6688 (3-fold serial dilution starting from 33.33 μM; 60 min) is a potent inhibitor of human recombinant HDAC1 and HDAC2 with an IC50 of 0.100 μM for HDAC2, demonstrating greater than 115-fold selectivity for HDAC1/2 over HDAC3[1].
BRD6688 exhibits kinetically selective inhibition of HDAC2 with a residence time half-life of 381 min, compared to 65 min for HDAC1[1].
BRD6688 (10 μM; 24 h) increases H4K12 and H3K9 histone acetylation in primary mouse forebrain neuronal cultures at 10 μM[1].
BRD6688 (5-10 μM) suppresses LTA4H gene expression in HREpiC cells under H/R conditions[2].
BRD6688 (5 μM) decreases LTB4 secretion in HREpiC cells under H/R conditions[2].
BRD6688 (5 μM) reduces the proportion of LTA4H-positive HREpiC cells[2].
BRD6688 (5 μM) reduces p-HDAC levels in HREpiC cells[2].
BRD6688 (5 μM) inhibits CK2 activity in HREpiC cells under hypoxia/reoxygenation[2].
BRD6688 inhibits p-HDAC2 and LTA4H expression in HDAC2-overexpressing HREpiC cells[2].
BRD6688 reduces LTB4 production in HDAC2-overexpressing HREpiC cells[2].
BRD6688 (5-10 μM; 48 h) reduces BLT1 expression but not BLT2 expression in RAW264.7 macrophages[2].
BRD6688 (5 μM; 2 days) promotes M2 phenotype and suppresses M1 phenotype in RAW264.7 macrophages[2].
Selective HDAC2 inhibition by BRD6688 and BRD4884 rescues memory deficits in impaired mice through increased H4K12 and H3K9 acetylation without affecting episodic memory[3].
BRD6688 (4 μM; 24 h) acts as a high-ranking activator of Srrm4-dependent microexon splicing in N2A cells[7].
BRD6688 (10 μM; 24 h) promotes microexon splicing inclusion with a relatively limited impact on global gene expression in N2A cells[7].
BRD6688 (10 μM) promotes microexon splicing largely independently of effects on Srrm4 expression, and its effects are additive with RDR00572 in N2A cells[7].
The HDAC 2 inhibitor BRD6688 (10-100 nM; 24 h) reduces the mRNA expression of IL-1β, TNF, MIP-1α, and MCP-1 in TNF-stimulated human PBMCs/monocytes in a dose-dependent manner[6].
The HDAC 2 inhibitor BRD6688 (10-100 nM; 24 h) significantly reduces the protein secretions of IL-1β and MCP-1 from TNF-stimulated human PBMCs/monocytes, but does not affect secreted TNF, MIP-1α, RANTES, IFN-γ, or IL-10 levels[6].
The HDAC 2 inhibitor BRD6688 (10-1000 nM; 10 days) significantly reduces the bone-resorbing activity of TNF-stimulated human osteoclasts at 1000 nM, but has minimal effect on osteoclast formation in the absence of TNF[6].
BRD6688 (10 nM; 10 days) reduces the mRNA expression of osteoclast-related factors TRAF-6, TRAP, Cathepsin K, and DC-STAMP at day 14 in TNF-stimulated human osteoclasts, but does not affect MCP-1, MIP-1α, or RANTES expression[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW264.7
-
Concentration:5 μM
-
Incubation Time:48 h
-
Result:Remarkably decreased mRNA expression of M1 macrophage markers (IL1B, IL6, TNF, IL12A, NOS2).
Restored the expression of M2 markers (IL10, TGFB1, ARG1, PDGFA) in RAW264.7 cells.
-
Cell Line:Human peripheral blood mononuclear cells (PBMCs)/monocytes
-
Concentration:10 nM; 100 nM
-
Incubation Time:24 h
-
Result:Reduced IL-1β relative mRNA expression to approximately 0.07 at 10 nM and 0.05 at 100 nM, compared to approximately 0.09 in vehicle control.
Reduced TNF relative mRNA expression to approximately 1.1 at 10 nM and 1.0 at 100 nM, compared to approximately 1.5 in control.
Reduced MIP-1α and MCP-1 mRNA expression in a dose-dependent manner.
Did not significantly alter IL-10 mRNA expression.
-
Cell Line:Human peripheral blood mononuclear cells (PBMCs)/monocytes
-
Concentration:10 nM; 100 nM
-
Incubation Time:24 h
-
Result:Significantly reduced protein levels of IL-1β and MCP-1 in cell supernatant.
Did not affect secreted levels of TNF, MIP-1α, RANTES, IFN-γ, or IL-10.
-
Cell Line:Human osteoclast progenitors
-
Concentration:10 nM; 100 nM; 1000 nM
-
Incubation Time:10 days
-
Result:Diminished osteoclast activity in the presence of TNF (10 ng/mL), with significant reduction in surface resorption at 1000 nM.
Reduced area of dentine resorption by approximately 50% when HDAC 2 was suppressed alone.
Had very little effect on osteoclastic formation in the absence of TNF.
-
Cell Line:Human osteoclasts
-
Concentration:10 nM
-
Incubation Time:10 days
-
Result:Reduced mRNA expression of TRAF-6, TRAP, Cathepsin K, and DC-STAMP at day 14.
Had no significant effect on MCP-1, MIP-1α, or RANTES.
In Vivo
BRD6688 (1 mg/kg; i.p.; daily; 10 days) significantly attenuates Paclitaxel (HY-B0015)-induced mechanical allodynia and partially reverses spinal glutamate accumulation in a rat model of chemotherapy-induced peripheral neuropathy[4].
Pharmacological inhibition of Hdac2 by BRD6688 (1 mg/kg; i.p.; single dose; 6 h before extinction training) before extinction training reduces spontaneous fear memory recovery and decreases Acan/Aggrecan expression in wild-type mice, but this effect is occluded in PV+ cell-specific Hdac2 conditional knockout mice[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CK-p25 (male, 3 months old, induced for 6 weeks)[1]
-
Dosage:1 mg/kg
-
Administration:i.p.; daily; 10 days
-
Result:Restored the freezing response to normal levels compared to vehicle-treated non-induced p25 littermates.
Increased H4K12 acetylation in hippocampal CA1 neurons compared to the vehicle-treated group.
-
Animal Model:Sprague-Dawley rats (male, 200-250 g, Paclitaxel-induced painful neuropathy)[4]
-
Dosage:1 mg/kg
-
Administration:i.p.; daily; 10 days
-
Result:Significantly suppressed Paclitaxel-induced mechanical allodynia measured by paw withdrawal threshold compared with vehicle.
Partially reversed increased glutamate concentration in the spinal dorsal horn compared with vehicle.
Reduced YY1 expression.
-
Animal Model:Wild-type Hdac2lox littermates and PV-Cre; Hdac2lox/lox mice (adult males, mixed 129sv/C57BL/6J background, postnatal day 60)[5]
-
Dosage:1 mg/kg
-
Administration:i.p.; single dose; 6 h before extinction training
-
Result:In wild-type Hdac2lox mice, presented significantly less freezing behavior at the extinction retrieval test (P = 0.0030) but not at the fear renewal test (P = 0.1246) compared to vehicle-injected mice.
In PV-Cre; Hdac2lox/lox mice, did not lead to a significant difference in freezing behavior during the retrieval test (P = 0.0850) or the renewal test (P = 0.6733) compared to vehicle.
In wild-type mice, significantly decreased the number of Acan mRNA molecules in PFC PV+ cell somata (P = 0.0303) and the proportion of PV+ cells enwrapped by Aggrecan+ nets (P = 0.0317) 17 h after injection.
Chemical Information
-
CAS No. 1404562-17-9
-
Appearance Solid
-
Molecular Weight 282.34
-
Formula C16H18N4O
-
Color Off-white to light yellow
-
SMILES
O=C(N1CCCC1)NC2=C(N)C=CC(C3=CC=NC=C3)=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (354.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (8.85 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (8.85 mM); Clear solution; Need ultrasonic
This protocol yields a clear solution of 2.5 mg/mL.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Nephrotoxicity Study
This protocol assesses nephrotoxicity by combining functional kidney injury readouts, urinary/tissue injury biomarkers, and renal histopathology. Serum creatinine and BUN reflect impaired kidney function, while KIM-1, NGAL, clusterin, osteopontin, IL-18, cystatin C, nephrin, Oat5, urinary protein, glucose, and alkaline phosphatase have been used to detect tubular injury in cisplatin-, gentamicin-, and acetaminophen-induced nephrotoxicity models.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
Purity & Documentation
-
Data Sheet (299 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Wagner FF, et al. Kinetically Selective Inhibitors of Histone Deacetylase 2 (HDAC2) as Cognition Enhancers. Chemical science. 2015 Jan 01;6(1):804-815. [Content Brief]
[6]. Algate K, et al. Histone deacetylases 1 and 2 inhibition suppresses cytokine production and osteoclast bone resorption in vitro. Journal of cellular biochemistry. 2020 Jan;121(1):244-258. [Content Brief]
[7]. Best AJ, et al. High-throughput sensitive screening of small molecule modulators of microexon alternative splicing using dual Nano and Firefly luciferase reporters. Nature communications. 2024 Jul 27;15(1):6328. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.5418 mL | 17.7091 mL | 35.4183 mL | 88.5457 mL |
| 5 mM | 0.7084 mL | 3.5418 mL | 7.0837 mL | 17.7091 mL | |
| 10 mM | 0.3542 mL | 1.7709 mL | 3.5418 mL | 8.8546 mL | |
| 15 mM | 0.2361 mL | 1.1806 mL | 2.3612 mL | 5.9030 mL | |
| 20 mM | 0.1771 mL | 0.8855 mL | 1.7709 mL | 4.4273 mL | |
| 25 mM | 0.1417 mL | 0.7084 mL | 1.4167 mL | 3.5418 mL | |
| 30 mM | 0.1181 mL | 0.5903 mL | 1.1806 mL | 2.9515 mL | |
| 40 mM | 0.0885 mL | 0.4427 mL | 0.8855 mL | 2.2136 mL | |
| 50 mM | 0.0708 mL | 0.3542 mL | 0.7084 mL | 1.7709 mL | |
| 60 mM | 0.0590 mL | 0.2952 mL | 0.5903 mL | 1.4758 mL | |
| 80 mM | 0.0443 mL | 0.2214 mL | 0.4427 mL | 1.1068 mL | |
| 100 mM | 0.0354 mL | 0.1771 mL | 0.3542 mL | 0.8855 mL |